Cargando…

A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer

BACKGROUND: Immune checkpoint inhibitors (ICI) have emerged as active therapies in the management of advanced RCC. While multiple studies have shown clinical activity of ICIs in clear cell histologies, the evidence to support their use in non-clear cell (ncc) subtypes is based on smaller prospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Palma dos Reis, Ana Filipa, Simão, Diana, Odeny, Thomas, Rodrigues, Chiara, Fontes-Sousa, Mário, da Luz, Ricardo, Chowdry, Rajasree Pia, Welsh, Sarah J., Paller, Channing, Barata, Pedro C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490428/
https://www.ncbi.nlm.nih.gov/pubmed/36212797
http://dx.doi.org/10.3233/KCA-210012
_version_ 1784793083811987456
author Palma dos Reis, Ana Filipa
Simão, Diana
Odeny, Thomas
Rodrigues, Chiara
Fontes-Sousa, Mário
da Luz, Ricardo
Chowdry, Rajasree Pia
Welsh, Sarah J.
Paller, Channing
Barata, Pedro C.
author_facet Palma dos Reis, Ana Filipa
Simão, Diana
Odeny, Thomas
Rodrigues, Chiara
Fontes-Sousa, Mário
da Luz, Ricardo
Chowdry, Rajasree Pia
Welsh, Sarah J.
Paller, Channing
Barata, Pedro C.
author_sort Palma dos Reis, Ana Filipa
collection PubMed
description BACKGROUND: Immune checkpoint inhibitors (ICI) have emerged as active therapies in the management of advanced RCC. While multiple studies have shown clinical activity of ICIs in clear cell histologies, the evidence to support their use in non-clear cell (ncc) subtypes is based on smaller prospective trials and retrospective analyses. OBJECTIVE: The objective of this review is to summarize the clinical outcomes of ICI-based therapies in ncc-subtypes and in tumors with sarcomatoid/rhabdoid features. METHODS: We performed a systematic literature search using PubMed, Google Scholar and ASCO databases. The keywords “renal cell cancer” and “immune checkpoint inhibitors” and equivalents were used and all original publications between July 2016 and July 2021 were included. RESULTS: We included a total of 14 publications, including two clinical trials and 12 case series. The most frequent histologies were papillary (up to 75-100%), unclassified (up to 34%) and chromophobe (up to 28%). ICI monotherapy showed some activity in both 1st and 2nd line with response rates up to 27%. ICI combination regimens yielded better activity than ICI monotherapy but, overall, a heterogeneous efficacy was noted across histologies. Overall, outcomes of ICIs were superior in tumors with sarcomatoid/rhabdoid features. CONCLUSION: The observed activity of ICI-based therapies was heterogeneous. Combination regimens, papillary subtype and sarcomatoid/rhabdoid features were associated with higher responses. These findings might help treatment decisions and require further validation.
format Online
Article
Text
id pubmed-9490428
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-94904282022-10-05 A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer Palma dos Reis, Ana Filipa Simão, Diana Odeny, Thomas Rodrigues, Chiara Fontes-Sousa, Mário da Luz, Ricardo Chowdry, Rajasree Pia Welsh, Sarah J. Paller, Channing Barata, Pedro C. Kidney Cancer Systematic Review BACKGROUND: Immune checkpoint inhibitors (ICI) have emerged as active therapies in the management of advanced RCC. While multiple studies have shown clinical activity of ICIs in clear cell histologies, the evidence to support their use in non-clear cell (ncc) subtypes is based on smaller prospective trials and retrospective analyses. OBJECTIVE: The objective of this review is to summarize the clinical outcomes of ICI-based therapies in ncc-subtypes and in tumors with sarcomatoid/rhabdoid features. METHODS: We performed a systematic literature search using PubMed, Google Scholar and ASCO databases. The keywords “renal cell cancer” and “immune checkpoint inhibitors” and equivalents were used and all original publications between July 2016 and July 2021 were included. RESULTS: We included a total of 14 publications, including two clinical trials and 12 case series. The most frequent histologies were papillary (up to 75-100%), unclassified (up to 34%) and chromophobe (up to 28%). ICI monotherapy showed some activity in both 1st and 2nd line with response rates up to 27%. ICI combination regimens yielded better activity than ICI monotherapy but, overall, a heterogeneous efficacy was noted across histologies. Overall, outcomes of ICIs were superior in tumors with sarcomatoid/rhabdoid features. CONCLUSION: The observed activity of ICI-based therapies was heterogeneous. Combination regimens, papillary subtype and sarcomatoid/rhabdoid features were associated with higher responses. These findings might help treatment decisions and require further validation. IOS Press 2022-08-04 /pmc/articles/PMC9490428/ /pubmed/36212797 http://dx.doi.org/10.3233/KCA-210012 Text en © 2022 – The authors. Published by IOS Press https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Systematic Review
Palma dos Reis, Ana Filipa
Simão, Diana
Odeny, Thomas
Rodrigues, Chiara
Fontes-Sousa, Mário
da Luz, Ricardo
Chowdry, Rajasree Pia
Welsh, Sarah J.
Paller, Channing
Barata, Pedro C.
A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer
title A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer
title_full A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer
title_fullStr A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer
title_full_unstemmed A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer
title_short A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer
title_sort systematic review of immune checkpoint inhibitors in non-clear-cell renal cancer
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490428/
https://www.ncbi.nlm.nih.gov/pubmed/36212797
http://dx.doi.org/10.3233/KCA-210012
work_keys_str_mv AT palmadosreisanafilipa asystematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer
AT simaodiana asystematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer
AT odenythomas asystematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer
AT rodrigueschiara asystematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer
AT fontessousamario asystematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer
AT daluzricardo asystematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer
AT chowdryrajasreepia asystematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer
AT welshsarahj asystematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer
AT pallerchanning asystematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer
AT baratapedroc asystematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer
AT palmadosreisanafilipa systematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer
AT simaodiana systematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer
AT odenythomas systematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer
AT rodrigueschiara systematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer
AT fontessousamario systematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer
AT daluzricardo systematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer
AT chowdryrajasreepia systematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer
AT welshsarahj systematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer
AT pallerchanning systematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer
AT baratapedroc systematicreviewofimmunecheckpointinhibitorsinnonclearcellrenalcancer